Payment overview · 2025
General Payments
$133.52
4 reported records · 4 companies
Healthcare provider profile · identity verified
Mary L Eschete, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · HOUMA, LA · NPI 1003856477
Verified facts
What the public records show
CMS Open Payments records show Mary L Eschete, MD received $133.52 in general payments during 2025 across 4 reported records.
Gilead Sciences, Inc. accounted for 58.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Delstrigo.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Descovy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vemlidy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Delstrigo by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Pifeltro by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $78.30 | 58.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.70 | 19.2% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $16.05 | 12.0% | 1 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $13.47 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $107.82 | 3 |
| Education | $25.70 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $78.30 | 1 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 160 | exact normalized | Medicare Part D |
| DELSTRIGO delstrigo |
2025 | Delstrigo | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
160 | 21 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 490 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 379 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 355 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 314 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 308 | 61 |
| Lisinopril | Lisinopril | 294 | 59 |
| Montelukast Sodium | Montelukast Sodium | 294 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 50 |
| Juluca | Dolutegravir/Rilpivirine | 223 | 20 |
| Furosemide | Furosemide | 215 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 30 |
| Carvedilol | Carvedilol | 192 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 36 |
| Famotidine | Famotidine | 174 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 166 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 34 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 160 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 32 |
| Tramadol Hcl | Tramadol Hcl | 149 | 22 |
| Topiramate | Topiramate | 134 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 128 | 13 |
| Valacyclovir | Valacyclovir Hcl | 128 | 19 |
| Jardiance | Empagliflozin | 126 | 27 |
| Metformin Hcl | Metformin Hcl | 125 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 18 |
| Ozempic | Semaglutide | 118 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 22 |
| Buspirone Hcl | Buspirone Hcl | 110 | 19 |
| Losartan Potassium | Losartan Potassium | 110 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 17 |
| Clonazepam | Clonazepam | 103 | 14 |
| Omeprazole | Omeprazole | 103 | 20 |
| Pregabalin | Pregabalin | 103 | 16 |
| Rifampin | Rifampin | 103 | 19 |
| Potassium Chloride | Potassium Chloride | 102 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 100 | 18 |
| Azithromycin | Azithromycin | 98 | 24 |
| Eliquis | Apixaban | 98 | 18 |
| Fluconazole | Fluconazole | 98 | 27 |
| Mirtazapine | Mirtazapine | 98 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 12 |
| Allopurinol | Allopurinol | 96 | 19 |
| Ketoconazole | Ketoconazole | 96 | 19 |
| Baclofen | Baclofen | 92 | 12 |
| Ethambutol Hcl | Ethambutol Hcl | 92 | 14 |
| Trazodone Hcl | Trazodone Hcl | 91 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 84 | suppressed |
| Ezetimibe | Ezetimibe | 84 | 16 |
| Tivicay | Dolutegravir Sodium | 84 | suppressed |
| Atenolol | Atenolol | 81 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 15 |
| Sertraline Hcl | Sertraline Hcl | 79 | 13 |
| Spironolactone | Spironolactone | 79 | 21 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 78 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 16 |
| Vascepa | Icosapent Ethyl | 74 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 13 |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 72 | suppressed |
| Isentress Hd | Raltegravir Potassium | 67 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 65 | suppressed |
| Meloxicam | Meloxicam | 64 | 12 |
| Ertapenem | Ertapenem Sodium | 62 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Mupirocin | Mupirocin | 61 | 17 |
| Januvia | Sitagliptin Phosphate | 57 | 13 |
| Cilostazol | Cilostazol | 56 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 56 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 15 |
| Abacavir | Abacavir Sulfate | 53 | suppressed |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Dapsone | Dapsone | 51 | suppressed |
| Finasteride | Finasteride | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | suppressed |
| Pifeltro | Doravirine | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 48 | 12 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 47 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 47 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | suppressed |
| Acyclovir | Acyclovir | 46 | suppressed |
| Alprazolam | Alprazolam | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 12 |
| Dovato | Dolutegravir Sodium/Lamivudine | 45 | suppressed |
| Dulera | Mometasone/Formoterol | 45 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Maraviroc | Maraviroc | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 37 | suppressed |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 36 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Nystatin | Nystatin | 35 | 20 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | suppressed |
| Ritonavir | Ritonavir | 31 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 30 | suppressed |
| Efavirenz | Efavirenz | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Cefadroxil | Cefadroxil | 27 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Lamivudine | Lamivudine | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 24 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 22 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Atazanavir Sulfate | Atazanavir Sulfate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Atovaquone | Atovaquone | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fosamprenavir Calcium | Fosamprenavir Calcium | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Serostim | Somatropin | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Renvela | Sevelamer Carbonate | 12 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Zidovudine | Zidovudine | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $133.52 · 4 records | Gilead Sciences, Inc. | Biktarvy, CABENUVA, DELSTRIGO, EGRIFTA, TROGARZO | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error